Hyrimoz

Digital Pharmacist

The RxWiki Digital Pharmacist stamp of approval lets you know that this content has been created and reviewed by a licensed pharmacist.

Hyrimoz is used to reduce the signs and symptoms of certain autoimmune conditions including several types of arthritis. Hyrimoz can lower the ability of your immune system to fight infections.

Hyrimoz Overview

Reviewed: December 2, 2018
Updated: 

Hyrimoz is a prescription medication used to treat rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), Crohn’s disease (CD), ulcerative colitis (UC), and plaque psoriasis (Ps).

Hyrimoz belongs to a group of drugs called tumor necrosis factor (TNF) blockers. TNF is a protein that is overproduced in certain autoimmune conditions, causing inflammation and tissue destruction in joints, mucosa or skin. In some cases of autoimmune disease, the immune system damages the body’s own tissues. Hyrimoz targets and blocks the protein that contributes to disease symptoms.

Hyrimoz is available as a solution for injection under the skin in a pre-filled syringe or pen and is usually given every 2 weeks.

Common side effects of Hyrimoz include upper respiratory infection, headache, and rash.

How was your experience with ?

First, a little about yourself

Tell us about yourself in a few words?

What tips would you provide a friend before taking ?

What are you taking for?

Choose one
  • Other

How long have you been taking it?

Choose one
  • Less than a week
  • A couple weeks
  • A month or so
  • A few months
  • A year or so
  • Two years or more

How well did work for you?

Did you experience many side effects while taking this drug?

How likely would you be to recommend to a friend?

Hyrimoz Drug Class

Back to Top

Hyrimoz is part of the drug class:

Hyrimoz FDA Warning

Back to Top

Warning: Serious Infections and Malignancy

Serious Infections:

Patients treated with adalimumab products including Hyrimoz, are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids.

Discontinue Hyrimoz if a patient develops a serious infection or sepsis.

Reported infections include:

  • Active tuberculosis (TB), including reactivation of latent TB. Patients with TB have frequently presented with disseminated or extrapulmonary disease. Test patients for latent TB before Hyrimoz use and during therapy. Initiate treatment for latent TB prior to Hyrimoz use.

  • Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Consider empiric anti-fungal therapy in patients at risk for invasive fungal infections who develop severe systemic illness.

  • Bacterial, viral and other infections due to opportunistic pathogens, including Legionella and Listeria.

Carefully consider the risks and benefits of treatment with Hyrimoz prior to initiating therapy in patients with chronic or recurrent infection.

Monitor patients closely for the development of signs and symptoms of infection during and after treatment with Hyrimoz, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy.

Malignancy:  

Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF-blockers including adalimumab products. Post-marketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have been reported in patients treated with TNF-blockers including adalimumab products. These cases have had a very aggressive disease course and have been fatal. The majority of reported TNF-blocker cases have occurred in patients with Crohn's disease or ulcerative colitis and the majority were in adolescent and young adult males. Almost all these patients had received treatment with azathioprine or 6-mercaptopurine (6–MP) concomitantly with a TNF-blocker at or prior to diagnosis. It is uncertain whether the occurrence of HSTCL is related to use of a TNF-blocker or a TNF-blocker in combination with these other immunosuppressants.